PIK3CA mutations are the most frequent actionable mutations in cervical cancers and have been approved by the US Food and Drug Administration (FDA) as a predictive biomarker for the use of the PI3K inhibitor, alpelisib [26]. The gene discussed is PIK3CA; the disease is cervical carcinoma.